The APBB1 Knockout A-549 Polyclonal Cells represent a heterogeneous population of A-549 cells genetically modified using CRISPR/Cas9 technology to disrupt the APBB1 gene. This polyclonal knockout pool provides a loss-of-function model for the Fe65 adaptor protein, enabling studies of APBB1-dependent signaling and transcriptional regulation without clonal selection. The product is supplied as a mixed population of edited cells, each carrying targeted gene disruptions, facilitating robust functional assays and reducing clonal artifacts.
The parental A-549 cell line, derived from human lung adenocarcinoma of a 58-year-old male, serves as a well-characterized model of alveolar type II pneumocytes. These adherent epithelial cells retain features relevant to respiratory biology and oncology, making them a standard platform for drug screening, cancer cell migration studies, and investigation of signaling pathways involved in lung carcinoma. The A-549 background supports expression of key epithelial and cancer-related markers, enabling dissection of tumor-suppressor and oncogenic networks.
APBB1 encodes Fe65, a scaffold protein that bridges the amyloid precursor protein (APP) intracellular domain to the Tip60/KAT5 histone acetyltransferase, forming a transcriptional complex that regulates genes governing cell adhesion, apoptosis, and DNA damage response. Fe65 is regulated by upstream factors such as p53, E2F1, and phosphorylation by cyclin-dependent kinases and Abl kinase signaling. Downstream, it modulates expression of target genes including GSK3B, KAI1/CD82, BIM, BAX, and p21, and interacts with proteins such as LRP1, Mena, Abl1, and SET. Disruption of APBB1 is expected to uncouple APP-Tip60 transcriptional complexes, thereby altering APP processing, DNA repair, and cell motility pathways.
In A-549 lung adenocarcinoma cells, APBB1 knockout provides a tool to dissect how Fe65-mediated transcription contributes to cancer cell properties. Since A-549 cells express APP and components of the DNA damage response, the loss of Fe65 is predicted to impair p53-dependent apoptosis and DNA repair via mechanisms involving Tip60 and downstream effectors such as BAX and p21. Moreover, Fe65 influences cell adhesion and migration through interactions with APP and Mena, suggesting that this knockout model can reveal novel aspects of metastatic potential in lung cancer.
Typical research applications include chromatin immunoprecipitation (ChIP)-qPCR for Fe65 target promoters, western blotting for APP and Tip60, RT-qPCR analysis of downstream transcripts (e.g., GSK3B, KAI1), and immunofluorescence detection of ??H2AX foci following genotoxic stress. The polyclonal pool is also suitable for wound healing assays, Annexin V apoptosis measurements, and co-immunoprecipitation of Fe65 interaction partners. This product is ideally suited for laboratories investigating the convergence of neurodegeneration and cancer signaling. For additional information, researchers are encouraged to contact Ascent Research.
